NEW YORK, June 21 - Proteome Systems and researchers at the University of Missouri-Columbia have agreed to jointly identify and study the proteins involved in resistance to cancer drugs using the company's proteomics platform, the company said Thursday.
Stephen Alexander, a molecular biologist at the university who has collaborated with Proteome Systems for almost 20 years, will use the slime mold Dictyostelium discoideum as a model system for studying the organism's cellular response to anticancer drugs.
Alexander said that his group will provide the biological expertise and the samples to Proteome Systems, which will employ its high-throughput 2-D gel electrophoresis and mass spectrometry platform to identify and characterize the proteins in the sample.
Because D. discoideum has about 15,000 genes, Alexander said, his group and researchers at Proteome Systems will be able to study the expressed proteins within a reasonable time frame. Alexander said the company has committed to funding his research for one year, but that the collaboration should last at least three years.
Having Proteome Systems fund the project is important Alexander added, because in general NIH would not fund a project focused predominantly on discovery science.
In a statement, Jenny Harry, the vice president for discovery at Sydney, Australia-based Proteome Systems, said that the Alexander group brings "a new perspective to solving problems in cancer. We are delighted to be working with a group of scientists who understand the value of proteomics to accelerate the discovery process."